WO2004017916A3 - Cardiovascular therapy composition including transfer factor and therapeutic methods including use of the composition - Google Patents

Cardiovascular therapy composition including transfer factor and therapeutic methods including use of the composition Download PDF

Info

Publication number
WO2004017916A3
WO2004017916A3 PCT/US2003/026427 US0326427W WO2004017916A3 WO 2004017916 A3 WO2004017916 A3 WO 2004017916A3 US 0326427 W US0326427 W US 0326427W WO 2004017916 A3 WO2004017916 A3 WO 2004017916A3
Authority
WO
WIPO (PCT)
Prior art keywords
composition
transfer factor
therapeutic methods
cardiovascular therapy
derived
Prior art date
Application number
PCT/US2003/026427
Other languages
French (fr)
Other versions
WO2004017916A2 (en
Inventor
William J Hennen
Original Assignee
4Life Res Lc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 4Life Res Lc filed Critical 4Life Res Lc
Priority to AU2003265620A priority Critical patent/AU2003265620A1/en
Publication of WO2004017916A2 publication Critical patent/WO2004017916A2/en
Publication of WO2004017916A3 publication Critical patent/WO2004017916A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
    • A61K31/198—Alpha-aminoacids, e.g. alanine, edetic acids [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/465—Nicotine; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/20—Milk; Whey; Colostrum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/44—Vessels; Vascular smooth muscle cells; Endothelial cells; Endothelial progenitor cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Abstract

A composition for use in cardiovascular therapy includes transfer factor. The transfer factor may be nonmammalian transfer factor, such as that derived from eggs, or mammalian transfer factor, such as that derived from colostrum. The composition may also include one or more of the following: an LDL receptor-binding element; a blood flow-enhancing element; a cholesterol reducing element; a fat oxidation prevention element, and an antioxidant. Treatment methods include enlisting the immune system of a subject receiving therapy to attack pathogens that cause inflammation of blood vessels or to otherwise reduce inflammation of blood vessels.
PCT/US2003/026427 2002-08-22 2003-08-22 Cardiovascular therapy composition including transfer factor and therapeutic methods including use of the composition WO2004017916A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2003265620A AU2003265620A1 (en) 2002-08-22 2003-08-22 Cardiovascular therapy composition including transfer factor and therapeutic methods including use of the composition

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US40535802P 2002-08-22 2002-08-22
US60/405,358 2002-08-22

Publications (2)

Publication Number Publication Date
WO2004017916A2 WO2004017916A2 (en) 2004-03-04
WO2004017916A3 true WO2004017916A3 (en) 2004-10-14

Family

ID=31946861

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/026427 WO2004017916A2 (en) 2002-08-22 2003-08-22 Cardiovascular therapy composition including transfer factor and therapeutic methods including use of the composition

Country Status (3)

Country Link
US (3) US7815943B2 (en)
AU (1) AU2003265620A1 (en)
WO (1) WO2004017916A2 (en)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6616942B1 (en) 1999-03-29 2003-09-09 Soft Gel Technologies, Inc. Coenzyme Q10 formulation and process methodology for soft gel capsules manufacturing
EP1608379A1 (en) * 2003-03-27 2005-12-28 Medicure Inc. Compositions for treating angina
US20080089877A1 (en) * 2003-08-14 2008-04-17 Udell Ronald G Super Absorption Coenzyme Q10
US6866868B1 (en) * 2003-09-15 2005-03-15 4Life Research, Lc Compositions including different types of transfer factor, methods for making the compositions, and methods of treatment using the compositions
US8124072B2 (en) 2003-09-29 2012-02-28 Soft Gel Technologies, Inc. Solubilized CoQ-10
US7169385B2 (en) * 2003-09-29 2007-01-30 Ronald G. Udell Solubilized CoQ-10 and carnitine
US8105583B2 (en) * 2003-09-29 2012-01-31 Soft Gel Technologies, Inc. Solubilized CoQ-10
US9028882B2 (en) 2005-05-02 2015-05-12 4Life Patents, Llc Nutraceutical gels
TWI380821B (en) * 2005-05-02 2013-01-01 4Life Patents Llc Transfer factor preparations and associated methods
US8343541B2 (en) * 2007-03-15 2013-01-01 Soft Gel Technologies, Inc. Ubiquinol and alpha lipoic acid compositions
MX355905B (en) 2010-11-23 2018-05-04 Pantheryx Inc Compositions and methods for treatment in broad-spectrum, undifferentiated or mixed clinical applications.
US8815310B2 (en) * 2011-01-10 2014-08-26 Morteza Naghavi Compositions for boosting metabolism, assisting weight loss, and promoting cardiovascular health
US20120177631A1 (en) * 2011-01-10 2012-07-12 Morteza Naghavi Composition for Health Promoting Compounds
US10004757B1 (en) 2017-09-22 2018-06-26 Nutri Vida, LLC Oral supplement

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6506413B1 (en) * 2001-04-30 2003-01-14 Joseph C. Ramaekers Compositions for treating animal diseases and syndromes

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816563A (en) * 1983-11-25 1989-03-28 Amtron, Inc. Process for obtaining transfer factor from colostrum, transfer factor so obtained and use thereof
CA1306946C (en) * 1985-11-25 1992-09-01 Hideo Tokoro Specific antibody-containing substance from eggs and method of production and use thereof
US5650418A (en) * 1990-06-04 1997-07-22 Therapy 2000 Therapeutic lysine salt composition and method of use
WO1992000093A1 (en) * 1990-07-02 1992-01-09 National Jewish Center For Immunology And Respiratory Medicine Transfer factor and methods of use
WO1998041195A2 (en) * 1997-03-20 1998-09-24 Coventry Group, Ltd. Nutritional supplement for cardiovascular health
US6022901A (en) * 1998-05-13 2000-02-08 Pharmascience Inc. Administration of resveratrol to prevent or treat restenosis following coronary intervention
US20020044942A1 (en) * 2000-09-18 2002-04-18 Chisolm Biological Laboratory, Llc Transfer factor composition and process for producing same
US6468534B1 (en) * 2000-09-21 2002-10-22 4Life Research, Lc Methods for obtaining transfer factor from avian sources, compositions including avian-generated transfer factor, and methods of use
US6693094B2 (en) * 2001-03-22 2004-02-17 Chrono Rx Llc Biguanide and sulfonylurea formulations for the prevention and treatment of insulin resistance and type 2 diabetes mellitus

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6506413B1 (en) * 2001-04-30 2003-01-14 Joseph C. Ramaekers Compositions for treating animal diseases and syndromes

Also Published As

Publication number Publication date
US9849157B2 (en) 2017-12-26
AU2003265620A8 (en) 2004-03-11
US20110033414A1 (en) 2011-02-10
AU2003265620A1 (en) 2004-03-11
US20040126432A1 (en) 2004-07-01
WO2004017916A2 (en) 2004-03-04
US10583168B1 (en) 2020-03-10
US7815943B2 (en) 2010-10-19

Similar Documents

Publication Publication Date Title
WO2004017916A3 (en) Cardiovascular therapy composition including transfer factor and therapeutic methods including use of the composition
SG152270A1 (en) Immunemodulating oligosaccharides
EP2332527A3 (en) Flavanoids and Isoflavanoids for the prevention and treatment of cardiovascular diseases
MY124559A (en) Anti-stress agent and functional food having anti-stress effect
NO20063328L (en) Use of a fatty acid composition comprising at least one of EPA and DHA or combinations thereof
MX2007013301A (en) Prophylactic/therapeutic agent for abnormalities of sugar/lipid metabolism.
HRP20050587A2 (en) Papaya puree and the use of the same
MY162337A (en) Transfer factor preparations and associated methods
WO2002081521A8 (en) Osteoprotegerin in milk
Ya White wines countering the metabolic syndrome
UA85548C2 (en) Use of aqueous extract of red vine leaves for preventing transition from clinically insignificant early stages of chronic venous insufficiency to stages i, ii or iii
WO2018154608A3 (en) Herbo-mineral formulation for the treatment of cardio vascular diseases and method of preparation thereof
Desai Goal explicitness and therapeutic outcome.
MD2518F1 (en) Medicamental preparation for reducing the cholesterol concentration in the blood
Prepelitsa et al. Radioprotective food additions in esophageal cancer patients radiotherapy
WO2003024384A3 (en) Improved methods for treatment with viral vectors
UA36188A (en) Method for correcting mitral valve failure
UA38235A (en) Mousse for therapeutic purpose "osoblyvyi" (special)
UA36187A (en) Method for treating chronic hepatitis

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP